CRP and COVID-19: Patients at risk of myocardial injury are older and have higher levels of hypertension, coronary artery disease, heart failure, and diabetes than patients with normal levels of Troponin I or T. Patients with COVID-19 and myocardial injury also have more severe systemic inflammation, with increased leukocyte counts and elevated levels of C-reactive protein (CRP), procalcitonin and other biomarkers of myocardial injury and stress, like creatine kinase, myoglobin, and N-terminal pro-B-type natriuretic peptide (16, 19, 33–36).